Navigation Links
Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment

NEW YORK, June 13, 2007--Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition. The findings are reported in a New Drug Class study published early Online and in an upcoming edition of The Lancet.

RA is the most common of all chronic inflammatory joint diseases, affecting 0·5–1% of the population in the industrialised world. Its typical symptoms are joint pain, stiffness, and swelling due to synovial inflammation and effusion.

Professor Josef Smolen, Division of Rheumatology, Medical University of Vienna, Austria and colleagues did a comprehensive study of the three new drugs—rituximab, abatacept and tocilizumab—and their effects as sole therapies or working in conjunction with existing treatments. They explore the pathogenesis of RA and the various routes for targeting treatments, including new therapeutic strategies, and also provide a comprehensive overview on ways to assess treatment response.

The authors say: "The enormous consequences of RA for the individual and for health-care and socioeconomic systems can only be prevented by effective treatments."

Traditional treatments for RA include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs). Only DMARDs, and to some extent glucocorticoids, can impede or stop the inflammatory and destructive disease processes. Methotrexate is the most widely used DMARD and is a cornerstone of most RA treatment regimens.

Of the three new drugs, rituximab and abatacept have been approved for RA treatment, while the third, tocilizumab, is in phase III trials. Rituximab targets the CD20 antigen in certain cells, and leads to a reduction in the CD20 cell count. Trials of rituximab showed it reduced RA symptoms by more than 50% for more tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Three New Drugs Mark New Era Rheumatoid Arthritis Treatment
(Date:9/2/2015)... , Sept. 2, 2015  Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at the Rodman & Renshaw ... NY at 9:35 a.m. ET on Thursday, September ... to the public via live audio webcast which can be ... corporate website at http://www.aethlonmedical.com . The webcast will be ...
(Date:9/2/2015)... -- Simplified Genetics , the only provider of consumer ... in the U.S., announced today the launch of two groundbreaking ... health found within specific genes – all with a simple ... The tests include Simply Fit and Simply ... that maps four key genes to provide individuals with the ...
(Date:9/2/2015)... , Sept. 2, 2015 Boston Scientific Corporation ... 2015 Morgan Stanley Global Healthcare Conference on September 17, in ... Mike Mahoney , chief executive officer, and Dan Brennan ... in a 30-minute question and answer session regarding the company ... A live webcast of the question and answer ...
Breaking Medicine Technology:Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference 2
... LAHTI, Finland, February 2 The demand for ... Russia. Demand for imported high-tech,medical devices is so ... products. The medical devices and equipment in most,Russian ... replacement.,These factors make the market very attractive also ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ... the treatment of breakthrough pain using Alexza,s Staccato(R) inhalation ... Phase I clinical testing and will be returned to ...
Cached Medicine Technology:Foreign Medical Devices are in High Demand in Russia 2Foreign Medical Devices are in High Demand in Russia 3Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration 2Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions ... Series. The series enables pharmaceutical researchers to participate in interactive programs in ...
(Date:9/2/2015)... ... 02, 2015 , ... RxNT , an innovative software ... enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app marks ... leader in health technology, RxNT was one of the first to build an ...
(Date:9/2/2015)... Covington, LA (PRWEB) , ... September 02, 2015 ... ... new President/CEO and Regulatory Affairs Officer following the departure of Kristen Dietz, former ... Medical Officer of Healtec® released the following statement welcoming Mr. Salot: “ Stanley ...
(Date:9/2/2015)... ... 02, 2015 , ... Splashtop Inc., the worldwide leader in ... mirroring and extending product line -- Splashtop Wired XDisplay . Complementing ... setting, the new Splashtop Wired XDisplay delivers enhanced performance and reliability for users ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and their ... documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps them ... reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s ...
Breaking Medicine News(10 mins):Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... A North Carolina team of doctors, nurses, hospitals and ... way to provide faster, more effective treatment for heart ... or fancy new equipment. But it does require competitors ... to move treatment forward empowering emergency services personnel ...
... condition, which is symptomless, can lead to heart attack ... More American women are suffering from asymptomatic peripheral artery ... risk for heart attack and stroke, a new study ... of an increase in common cardiovascular risk factors, namely ...
... from union benefit funds,Union coalition says Rite Aid wants union money, but ... ... They are telling conference attendees: Trust Rite Aid? Think Twice!, ... pharmacy benefits management company (Rite Aid,Solutions) at the International Foundation Employee Benefits ...
... TARRYTOWN, N.Y., Nov. 3 EpiCept Corporation,(Nasdaq and OMX ... a,conference call to discuss third quarter 2007 results and ... 8:30 a.m. EST. EpiCept,will release results for the three ... EST on Monday, November 5, 2007. (Logo: ...
... is disappointed with today,s ruling and we intend to ... at issue was the result of,highly competitive conditions in ... ruling on liability is thus profoundly,anti- competitive. AstraZeneca ... drugs and we firmly believe that we have acted ...
... Mexican Red Cross for Flood,Relief, WASHINGTON, Nov. 2 ... to provide $50,000 to the Mexican Red Cross to,assist ... than,800,000 people. Unusually heavy rains caused rivers to overflow ... was already waterlogged,after Hurricanes Dean and Felix., "Thousands ...
Cached Medicine News:Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 2Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 3Health News:Rite Aid's Fledgling Benefits Management Firm Hits Turbulence at Employee Benefits Conference in Anaheim 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 3Health News:Sister Red Cross Societies Help Each Other 2
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Medicine Products: